• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Republicans are more likely than Democrats to say they have a good friend in the other party

admin - Latest News - November 14, 2025
admin
15 views 20 secs 0 Comments




Despite a polarized, partisan political environment, most voters who consider themselves a member of a party say they have a close friend on the other side of the aisle, according to the latest national NBC News poll.



Source link

TAGS:
PREVIOUS
Man dies from a meat allergy caused by a tick bite
NEXT
Ancient RNA offers a snapshot of a mammoth's life 39,000 years ago
Related Post
November 14, 2025
DHS announces $10K bonuses for 'exemplary' TSA agents
September 23, 2025
Macron calls Trump after his motorcade blocks his route
November 26, 2025
Nov. 25, 2025, 6:33 PM ESTBy Berkeley Lovelace Jr.The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on 15 costly prescription drugs under Medicare, including Ozempic and Wegovy. The price cuts come through the Medicare drug price negotiation program created under the Inflation Reduction Act, which President Joe Biden signed into law in 2022. It’s different from President Donald Trump’s “most favored nation” drug pricing approach, which relies on executive orders and voluntary deals with drugmakers — not legislation. Trump recently announced such a deal with Novo Nordisk, the maker of Ozempic and Wegovy, to lower the price of the drugs in exchange for tariff relief.The Trump administration has been largely quiet about the Medicare price negotiation program.This is the second round of negotiations. Last year, the Biden administration reached deals on 10 prescription drugs, including several for heart disease and diabetes. Those price cuts are set to take effect in 2026. This latest round of price negotiations will go into effect in 2027.“President Trump directed us to stop at nothing to lower health care costs for the American people,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a news release. “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.” Drugmakers can choose not to strike deals under the negotiation program, but doing so would most likely mean withdrawing their drugs from Medicare — cutting them off from one of the nation’s largest markets. Drugmakers have challenged the program in court but so far have been unsuccessful. The negotiated prices are what Medicare will pay drugmakers for the medicines, not what patients will pay out of pocket. Those discounts will save taxpayers $12 billion, according to CMS. It’s expected to save Medicare enrollees $685 million in out-of-pocket costs in 2027. Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price:Ozempic, Rybelsus and Wegovy, for Type 2 diabetes and weight loss: $274 negotiated price, down from the $959 list price. (Negotiated prices for higher doses of Wegovy are $385.)Trelegy Ellipta, an asthma treatment: $175, down from $654.Xtandi, for prostate cancer: $7,004, down from $13,480.Pomalyst, a chemotherapy drug: $8,650, down from $21,744.Ofev, for idiopathic pulmonary fibrosis: $6,350, down from $12,622.Ibrance, a breast cancer drug: $7,871, down from $15,741.Linzess, a chronic constipation drug: $136, down from $539.Calquence, a cancer drug: $8,600, down from $14,228.Austedo and Austedo XR, for Huntington’s disease: $4,093, down from $6,623.Breo Ellipta, a COPD drug: $67, down from $397.Xifaxan, for diarrhea and irritable bowel syndrome: $1,000, down from $2,696.Vraylar, an antipsychotic drug: $770, down from $1,376.Tradjenta, a diabetes drug: $78, down from $488. Janumet and Janumet XR, diabetes drugs: $80, down from $526.Otezla, a psoriatic arthritis drug: $1,650, down from $4,722.The 15 drugs accounted for $42.5 billion, or 15%, of total Medicare Part D spending in 2024. Medicare Part D covers medications that people take at home, as opposed to those administered in a facility, such as IV chemotherapy. “The price negotiations look very reasonable to me,” said Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee. “It should hopefully provide some relief for taxpayers and beneficiaries in the long run.” Dusetzina said the $274 negotiated price for Ozempic and Wegovy is higher than the $250 price in Trump’s deal. “They should’ve gotten that deal for the taxpayers and the Medicare beneficiaries,” she said.The price cuts come as many Americans say the cost of prescription drugs is unaffordable.About 1 in 5 adults say they’ve skipped filling a prescription because it was too expensive, according to a survey published in July by health policy research group KFF. About 1 in 7 say they have cut pills in half or skipped doses of medicine in the last year because of the cost. Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
October 1, 2025
Sept. 30, 2025, 12:04 PM EDTBy Kaan OzcanNew cases of cancer have been rising among younger people, worrying patients and doctors about causes. A new study suggests increasing numbers of cases of early onset cancer are largely due to improved and more routine screening, while mortality rates among younger people haven’t changed.The study, published Monday in JAMA Internal Medicine, compared rates of new diagnoses over the past three decades to mortality rates of the fastest-rising cancers in adults under 50. Of the eight cancers the research team studied, only two, colorectal and endometrial, showed increases in deaths. Other cancers included thyroid, anal, pancreatic, kidney, myeloma and small intestine. While breast and kidney cancers have increased in incidence, the mortality rates across all age groups have decreased in recent years.In fact, invasive breast cancer has been increasing faster in women under 50 than women over 50, at around a 1.4% increase per year from 2012 to 2021, according to the American Cancer Society. Similarly, colorectal cancer rates increased 2.4% per year in adults under 50 years and by 0.4% in adults 50-64 from 2012 to 2021. However, deaths have been halved for both because of earlier detection and improved treatment such as immunotherapies.Advances in screening technology and recommended screening at younger ages have allowed doctors to detect tumors at their earliest stages, including cases that may not ever negatively affect a person’s health.Dr. H. Gilbert Welch, senior investigator at the Center for Surgery and Public Health at Mass General Brigham hospital and a co-author of the study, said the harder doctors look for cancer, the more they are bound to find. “There really isn’t much more cancer out there,” Welch said. “We’re just finding stuff that’s always been there. That’s particularly true in things like the thyroid and the kidney.”The increase in “diagnostic scrutiny” for cancer adds to the uptick in some cancer case numbers. “Largely, what’s going on here is that people are getting tested more, and they’re getting more, if you will, powerful tests that can resolve smaller and smaller abnormalities,” he said. “This is largely simply unearthing things that have always been there.”Last year, the highly influential U.S. Preventive Services Task Force lowered the recommended age for first breast cancer screenings to 40, down from 50. And as deaths from colon cancer among people ages 45 to 49 ticked up, in 2021 the recommended age to start screening dropped from 50 to 45. Dr. Ahmed Jemal, senior vice president for surveillance, prevention and health services research at the American Cancer Society, said rising incidence rates can’t simply be chalked up to more and improved screening. Some of the causes are diet, obesity and physical inactivity.The study also pointed out that unnecessary treatments, such as surgery or radiation or chemotherapy, for cancers that aren’t “clinically meaningful” can cause multiple burdens for younger patients, Jemal said. A clinically meaningful cancer is considered dangerous and could spread if it is untreated. “You create not only cost burden, but you create anxiety,” Jemal said. Dr. Philippe E. Spiess, chief of surgery at Moffitt Cancer Center in Tampa, Florida, said the psychosocial aspect of cancer is another significant consequence. “Once a patient physically knows they have a mass, there is a significant burden that you have related to knowing that,” he said.Rather than intervene with every cancer doctors find, Spiess said, it’s important for doctors to assess whether patients’ cancers are dangerous and at risk of harming them. If tumors are small enough to be considered nonlethal, doctors should work with patients to monitor and continually assess their risk.“As long as the patient is committed to observation and surveillance, I think the consideration there is that you’re really not losing anything,” Spiess said.Kaan OzcanKaan Ozcan is an intern with NBC News’ Health and Medical Unit. 
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved